Business
Neurothera Labs Announces Results of AGM
(TheNewswire)   January 8, 2026 – TheNewswire - Vancouver, British Columbia, ...
About this update from Neurothera Labs Inc.
[{"type":"text","content":"Neurothera Labs Announces Results of AGM\n(TheNewswire)\n\n\n \n\n\n\nJanuary 8, 2026 – TheNewswire -\nVancouver, British Columbia, Canada –\nNeurothera Labs Inc. (TSXV: NTLX) (“Neurothera” or the\n“Company”), a clinical-stage biotech company and a majority-owned\nsubsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce the\nresults of its annual and special meeting of shareholders\n(“AGM”) held today. \n\n\nAll of the nominee directors listed in Neurothera’s\nmanagement information circular dated December 4, 2025 (the\n“Circular”) were elected as directors. Furthermore, shareholders of\nthe Company voted in favour of appointing Dale Matheson Carr-Hilton\nLabonte LLP as auditors of the Company for the ensuing year and\nauthorizing the directors to fix their remuneration. \n\n\nShareholders of the Company also voted in favour of\nauthorizing the Company to effect a consolidation of the common shares\nof the Company (“Common\nShares”) on the basis of one\npost-consolidation Common Share for up to one hundred (100)\npre-consolidation Common Shares, as determined by the directors of the\nCompany, in their sole discretion. For greater\ncertainty and notwithstanding the foregoing, the directors of the\nCompany have not yet determined to effect the consolidation and may\nelect not to proceed with the consolidation, in their sole discretion\n(subject to fiduciary and statutory duties). The directors will\ncontinue to assess market conditions and the interests of the Company\nand shareholders before proceeding to effect the consolidation, if at\nall. To be effective, the consolidation must also be approved by the\nTSX Venture Exchange. \n\n\nLastly, shareholders of the Company approved by\nordinary resolution the adoption of the 20% fixed equity incentive\nplan (the “Equity Incentive\nPlan”), as further described in the Circular.\nAdoption of the Equity Incentive Plan is subject to final TSX Venture\nExchange approval. \n\n\nAbout Neurothera Labs Inc. \n\n\nNeurothera Labs Inc. (TSXV: NTLX) is a clinical-stage\npharmaceutical company focused on developing novel therapeutics for\ncentral nervous system disorders and other underserved health\nconditions through collaborations and innovative combinations. \n\n\nFor further...